|
|
ImmunoGen, Inc.
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
of interest" In addition , there is a high interest in Immunogen, a bioengineer who developed ADC . In particular, at the end of last year , Elahere (mirvetuximab soravtansine-gynx), the first ADC for platinum - resistant ovarian cancer, received US approval, and blood cancer treatment pivekimab is also in phase 2 development, with a market cap of over $ 1 billion ." |
|
|
return to message board, top of board |
| Msg # | Subject | Author | Recs | Date Posted |
| 55252 | Re: of interest | jv08201 | 2 | 2/3/2023 8:54:51 AM |
